Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

<< Previous

Bullboard Posts

Next >>

Post by Jon9800on Jul 04, 2022 7:05am

123 Views

Post# 34798637

$HEM outstanding shares and public float idea

$HMTXF has successfully offered and issued an aggregate of 68.2 Million to the shareholders globally in terms of outstanding shares, and a total of 19.34 Million shares are available for the general public for daily trade at any point of time.

<< Previous

Bullboard Posts

Next >>

TELUS adds 347K customers in Q3